| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 1, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Epiduo® Gel (adapalene and benzoyl...
-
Aug 23, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Suprep® (sodium...
-
Aug 17, 2016
Perrigo Company plc (NYSE: PRGO; TASE) announced today that it has agreed to acquire Peachtree City, Georgia-based, Geiss, Destin & Dunn, Inc. ("GDD"), a small national distributor of...
-
Aug 10, 2016
Delivered second quarter reported (GAAP) net sales of $1.48 billion and adjusted (non-GAAP) net sales of $1.44 billion, excluding sales of $44 million from held-for-sale businesses* Delivered...
-
Aug 8, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has completed the previously announced divestiture of its U.S. Vitamins, Minerals & Supplements (VMS) business to International...
-
Aug 2, 2016
Perrigo Company plc (NYSE: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on September 13, 2016 to shareholders of record on...
-
Jul 27, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its second quarter calendar year 2016 on Wednesday, August 10th, 2016 at approximately 6:00 a.m....
-
Jul 20, 2016Appoints John Wesolowski as Acting General Manager, Rx Pharmaceuticals
Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products®, today announced the departure of Douglas Boothe,...
-
Jul 18, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that the U.S. Food and Drug Administration has approved the company's ANDA for omeprazole and sodium bicarbonate capsules, 20mg/1100mg. This...
-
Jun 21, 2016
Perrigo Company plc (NYSE: PRGO; TASE), today announced it has received final U.S. Food and Drug Administration ("FDA") clearance for three milk-based, store brand non-GMO infant formulas....
-
Jun 20, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has reached a definitive agreement to sell its U.S. Vitamins, Minerals & Supplements (VMS) business to International Vitamin...
-
Jun 16, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received final U.S. Food and Drug Administration ("FDA") approval for the generic version of Mallinckrodt Pharmaceuticals' Ofirmev®...
-
Jun 16, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the 16th Annual Oppenheimer Consumer Conference at 9:05 AM EDT on...
-
Jun 13, 2016
Perrigo Company plc (NYSE: PRGO; TASE) announced that it has filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) for ingenol mebutate gel (0.015% and...
-
May 31, 2016
Perrigo Company plc (NYSE: PRGO; TASE) and its partner West-Ward Pharmaceuticals Corp. today announced the U.S. Food and Drug Administration has approved, and that Perrigo has launched,...
-
May 18, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the UBS Global Healthcare Conference at 1:30 PM EDT on Tuesday, May...
-
May 16, 2016- No changes to adjusted results or adjusted guidance from original earnings release issued on May 12, 2016
The full corrected release reads as follows: PERRIGO COMPANY PLC REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS Delivered record first quarter adjusted net sales of $1.34 billion excluding VMS sales of
-
May 11, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its first quarter calendar year 2016 on Thursday, May 12, 2016 at approximately 6:00 a.m. (ET)....
-
May 3, 2016
Perrigo Company (NYSE: PRGO; TASE) and its partner Allergan plc (NYSE: AGN) today announced the launch of guaifenesin 1200mg and dextromethorphan HBr 60mg extended-release tablets, the first OTC...
-
May 2, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received final U.S. Food and Drug Administration ("FDA") approval for the generic version of Valeant Pharmaceutical International,...
-
Apr 28, 2016Announces Resignation of Marc Coucke as Executive Vice President and General Manager Branded Consumer Healthcare
Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products®, today announced that Mr. Sharon Kochan, Perrigo's...
-
Apr 26, 2016
Perrigo Company plc (NYSE: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on June 14, 2016 to shareholders of record on May 27, 2016.
-
Apr 25, 2016Names Laurie Brlas as Chairman of the Board of Directors
Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products®, today announced the appointment of John T. Hendrickson...
-
Apr 22, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today released the following statement regarding recent media coverage concerning Chairman and CEO Joseph C. Papa: "We are aware of the speculation regarding...
-
Apr 12, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced the first-to-market launch of the over-the-counter (OTC) store brand equivalent to Glucerna® aseptic adult nutritional shake for people with...